198
Participants
Start Date
March 10, 2014
Primary Completion Date
March 15, 2021
Study Completion Date
December 31, 2025
LY2835219
Administered orally.
Letrozole
Administered orally.
Anastrozole
Administered orally.
Tamoxifen
Administered orally.
Exemestane
Administered orally.
Everolimus
Administered orally.
Trastuzumab
Administered IV infusion.
LY3023414
Administered orally.
Fulvestrant
Administered IM.
Pertuzumab
Administered IV infusion.
Loperamide
Administered orally.
Endocrine therapy
Endocrine therapy administered orally.
Columbia University College of Phys & Surgeons, New York
Memorial Sloan Kettering Cancer Center, New York
Univ of Pittsburgh Cancer Inst. (UPCI), Pittsburgh
University of North Carolina at Chapel Hill, Chapel Hill
Peggy and Charles Stephenson Oklahoma Cancer Center, Nashville
Tennessee Oncology PLLC, Nashville
Highlands Oncology Group - Duplicate 2, Rogers
Providence Cancer Center Oncology Hematology Care, Portland
University of California - San Diego, La Jolla
Dana Farber Cancer Institute, Boston
Mayo Clinic, Rochester
Vanderbilt University Medical Center, Nashville
South Texas Accelerated Research Therapeutics (START), San Antonio
Eli Lilly and Company
INDUSTRY